Bicara Therapeutics Valuation
| BCAX Stock | 14.06 0.74 5.00% |
At this time, the firm appears to be undervalued. Bicara Therapeutics shows a prevailing Real Value of USD17.95 per share. The current price of the firm is USD14.06. Our model approximates the value of Bicara Therapeutics from analyzing the firm fundamentals such as current valuation of 522.03 M, and Return On Equity of -0.27 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bicara Therapeutics' valuation include:
Undervalued
Today
Please note that Bicara Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Bicara Therapeutics is based on 3 months time horizon. Increasing Bicara Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bicara Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bicara Stock. However, Bicara Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.06 | Real 17.95 | Target 30.8 | Hype 14.07 |
The intrinsic value of Bicara Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bicara Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bicara Therapeutics Common helps investors to forecast how Bicara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bicara Therapeutics more accurately as focusing exclusively on Bicara Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bicara Therapeutics' intrinsic value based on its ongoing forecasts of Bicara Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bicara Therapeutics' closest peers.
Bicara Therapeutics Cash |
|
Bicara Therapeutics Total Value Analysis
Bicara Therapeutics Common is currently forecasted to have valuation of 522.03 M with market capitalization of 810.77 M, debt of 738 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bicara Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
522.03 M | 810.77 M | 738 K |
Bicara Therapeutics Asset Utilization
One of the ways to look at asset utilization of Bicara is to check how much profit was generated for every dollar of assets it reports. Bicara Therapeutics Common shows a negative utilization of assets of -0.19 percent, losing USD0.001859 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bicara Therapeutics Common shows how unproductive it operates for each dollar spent on its assets.Bicara Therapeutics Profitability Analysis
Based on Bicara Therapeutics' profitability indicators, Bicara Therapeutics Common may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Bicara Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -61.2 M | Current Value -64.3 M | Quarterly Volatility 10.7 M |
For Bicara Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bicara Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bicara Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bicara Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bicara Therapeutics over time as well as its relative position and ranking within its peers.
Bicara Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Bicara Therapeutics is estimated to be -0.6888 with future projections ranging from a low of -0.79 to a high of -0.58. Bicara Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at 5.38. Please be aware that the consensus of earnings estimates for Bicara Therapeutics Common is based on EPS before non-recurring items and includes expenses related to employee stock options.Bicara Therapeutics Earnings Estimation Breakdown
The calculation of Bicara Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Bicara Therapeutics is estimated to be -0.6888 with the future projection ranging from a low of -0.79 to a high of -0.58. Please be aware that this consensus of annual earnings estimates for Bicara Therapeutics Common is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.79 Lowest | Expected EPS | -0.58 Highest |
Bicara Therapeutics Earnings Projection Consensus
Suppose the current estimates of Bicara Therapeutics' value are higher than the current market price of the Bicara Therapeutics stock. In this case, investors may conclude that Bicara Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Bicara Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 12 | 0.0% | 0.0 | -0.6888 | 5.38 |
Bicara Therapeutics Ownership Allocation
Bicara Therapeutics holds a total of 54.78 Million outstanding shares. The majority of Bicara Therapeutics Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bicara Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bicara Therapeutics. Please pay attention to any change in the institutional holdings of Bicara Therapeutics Common as this could imply that something significant has changed or is about to change at the company. Also note that nearly four million one hundred thirty thousand five hundred fifty-nine invesors are currently shorting Bicara Therapeutics expressing very little confidence in its future performance.Bicara Therapeutics Profitability Analysis
Net Loss for the year was (68 M) with profit before overhead, payroll, taxes, and interest of 0.About Bicara Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Bicara Therapeutics. We calculate exposure to Bicara Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bicara Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -50.4 K | -47.9 K |
Bicara Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Bicara Therapeutics Common and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bicara we look at many different elements of the entity such as Bicara's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bicara Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bicara Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bicara Therapeutics' worth.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.